Ovid Therapeutics Inc. (OVID) Stock

Ovid Therapeutics Inc. (OVID) is a Healthcare stock trading at $2.79 (as of 2026-08-21), with a market capitalization of $545.86M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing drug candidates for neurological disorders. Its pipeline includes candidates such as OV101 for fragile X syndrome and OV329 and OV350 for seizure-related conditions, along with other programs including gene therapy and small-molecule approaches, with clinical development conducted in the U.S.

Understand Ovid Therapeutics Inc.: how it makes money

Ovid Therapeutics develops biopharmaceutical medicines for neurological disorders, and its current monetization sources (based on disclosed line items) are royalty agreements and license and other revenue.

Its profit model, as reflected in the latest disclosed revenue line items, depends on royalty and license and other revenue rather than meaningful product revenue, while the company continues advancing multiple clinical-stage drug candidates.

Revenue by segment (latest quarter)
Royalty$0.0B
LicenseOther$0.0B

Business quality (Weak): Clinical-stage biopharma with multiple neurological disorder programs (OV101, OV329, OV350, OV882, OV815). Latest quarter shows 0.0B revenue and a very negative operating margin, so near-term results appear to be driven by trial progress rather than revenue generation.

Bull case

  • Phase 2A development for OV101 in fragile X syndrome: OV101 is in Phase 2A clinical trials for the treatment of fragile X syndrome.
  • Broad neurological pipeline across multiple mechanisms: The company is developing OV329 for seizures associated with tuberous sclerosis complex and infantile spasms, OV350 for epilepsies, and OV882 (short hairpin RNA gene therapy) for angelman syndrome.
  • Disclosed safety signal counts for specific repeat dose cohorts: In the provided adverse event counts for certain repeat dose cohorts, headache, drowsiness, and metallic taste each show a count of 1.

Bear case

  • No reported revenue in the latest quarter: For the period ending 2025-09-30, reported revenue is 0.0B, with royalty and license and other revenue also shown as 0.0B.
  • Large operating losses: The latest quarter operating margin is -9487.1.
  • Clinical outcomes are uncertain: The business is built around developing drug candidates, including multiple programs in clinical trials, so future efficacy and safety results are not yet known from the provided facts.
Valuation — source: SEC EDGAR (first-party)
Price$2.79
Market Cap$545.86M
Price / Book2.60
Price / Sales631.05
FCF Yield-5.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$7.25M
Net Margin-240.1%
Revenue Growth (YoY)1181.3%
FCF Growth (YoY)-31.6%
Financial Health — source: SEC EDGAR
Altman Z-Score7.57 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderJupiter Topco LLC ($55.90M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMargaret Alexander
Employees23
CountryUS
IPO Date2017-05-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Aquestive Therapeutics, Inc. (AQST)
  • Shattuck Labs, Inc. (STTK)
  • Evolus, Inc. (EOLS)
  • ARS Pharmaceuticals, Inc. (SPRY)
  • Sagimet Biosciences Inc. (SGMT)
  • NovaBridge Biosciences (NBP)
  • Prelude Therapeutics Incorporated (PRLD)
  • MapLight Therapeutics, Inc. (MPLT)
OVID earnings history · OVID institutional & insider holders · OVID KPIs & operating metrics · OVID financials · OVID investor presentations & press releases · OVID SEC filings · OVID peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.